(Nasdaq: ARVN), a clinical - stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the first participant has been dosed in its Phase 1/2 ...

Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced data published in the Proceedings of the ...

Evidence for peri-transplant RT comes mainly from retrospective studies and suggests that its value is concentrated in ...

Kalidi Biotherapeutics is betting that a heavily engineered vaccinia virus can do what CAR-T therapy has largely failed to do: systemically ...

Merck MRK announced that the FDA has expanded the label of its oral cancer drug Welireg (belzutifan) for a third indication ...

Puma Biotechnology has launched the phase 2 ALISCA-Lung2 trial (PUMA-ALI-4202; NCT07465757) evaluating the investigational ...

Over the past decade, AstraZeneca AZN has built a broad oncology franchise spanning multiple cancer types, including lung, ...

The study is designed to further evaluate the efficacy and safety of cadonilimab as first-line therapy for advanced gastric cancer across geographically and ethnically diverse patient populations ...

Immunotherapy has transformed the treatment of many cancers, but breast cancer has remained stubbornly resistant to one of ...

The approval shows 26% progression risk reduction but lacks statistically significant overall survival data, limiting its ...

Merck ( MRK) and Eisai have received U.S. FDA approval for WELIREG (belzutifan) in combination with LENVIMA (lenvatinib) for certain adults with previously treated advanced renal cell carcinoma with a ...

Merck & Co. has scored an FDA approval for its blockbuster-to-be Welireg to move into second-line treatment of kidney cancer, ...